Please use this identifier to cite or link to this item:
Title: Aβ-amyloid and tau imaging in dementia
Austin Authors: Villemagne, Victor L ;Doré, Vincent ;Bourgeat, Pierrick;Burnham, Samantha C;Laws, Simon;Salvado, Olivier;Masters, Colin L ;Rowe, Christopher C 
Affiliation: Department of Molecular Imaging & Therapy, Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia
The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
CSIRO, Health & Biosecurity Flagship, The Australian eHealth Research Centre, Brisbane, Queensland, Australia
eHealth, CSIRO Health and Biosecurity, Floreat, Western Australia, Australia
Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
Issue Date: Jan-2017 2016-10-01
Publication information: Seminars in Nuclear Medicine 2017; 47(1): 75-88
Abstract: The introduction of in vivo imaging of Aß-amyloid pathology more than a decade ago, transformed the assessment of Alzheimer disease (AD) allowing the evaluation of A? deposition over time by providing highly accurate, reliable, and reproducible quantitative statements of regional or global A? burden in the brain to the extent that A? imaging has already been approved for clinical use and is being used for both patient recruitment and outcome measure in current anti-?? therapeutic trials. A? imaging studies have deepened our insight into A? deposition, showing that A? accumulation is a slow and protracted process extending for more than two decades before the onset of the clinical phenotype. Although cross-sectional evaluation of ?? burden does not strongly correlate with cognitive impairment in AD, ?? burden does correlate with memory impairment and a higher risk for cognitive decline in the aging population and mild cognitive impairment subjects. These associations suggest that ?? deposition is not a benign process. The recent addition of selective tau imaging will allow to elucidate if these effects are directly associated with ?? deposition or if they are mediated, in toto or in parte, by tau as it spreads out of the mesial temporal lobe into neocortical association areas. The combination of A? and tau imaging studies would likely help elucidate the relationship or interplay between the two pathologic hallmarks of the disease. Longitudinal observations to assess their potential independent or synergistic, sequential or parallel effects on cognition, disease progression, and other disease-specific biomarkers of neurodegeneration would be required to further clarify the respective role of ?? and tau deposition play in the course of AD.
DOI: 10.1053/j.semnuclmed.2016.09.006
ORCID: 0000-0002-2605-4766
PubMed URL:
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Nov 25, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.